Oncolytics Biotech Gestione

Gestione criteri di controllo 3/4

Oncolytics Biotech Il CEO è Wayne Pisano, nominato in Jun2024, ha un mandato di meno di un anno. possiede direttamente 0.25% delle azioni della società, per un valore di $ 190.37K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.9 anni e 5.5 anni.

Informazioni chiave

Wayne Pisano

Amministratore delegato

CA$165.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.2%
Durata media del management	2.9yrs
Durata media del Consiglio di amministrazione	5.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Oncolytics Biotech reports Q1 results

May 07

AMMINISTRATORE DELEGATO

Wayne Pisano (69 yo)

less than a year

Mandato

CA$165,010

Compensazione

Mr. Wayne F. Pisano, MBA, is Interim Chief Executive Officer at Oncolytics Biotech Inc. since June 24, 2024. He has been an Independent Director of Altimmune, Inc. since August 30, 2018. Mr. Pisano had bee...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Wayne Pisano	Interim CEO & Chairman of the Board	less than a year	CA$165.01k	0.25% $ 190.4k
Kirk Look	Chief Financial Officer	12yrs	CA$1.32m	1.16% $ 894.9k
Matthew Coffey	President	less than a year	CA$2.25m	0.12% $ 96.6k
Thomas Heineman	Chief Medical Officer	2.9yrs	CA$1.36m	0.67% $ 517.4k
Allison Hagerman	Vice President of Product Development	6.1yrs	CA$727.64k	0.67% $ 517.9k
Amy Levin	Vice President of Clinical Operations	1.8yrs	CA$683.55k	Nessun dato
Jon Patton	Director of Investor Relations & Communication	no data	Nessun dato	Nessun dato
John Lievonen	Consultant	5.5yrs	CA$25.98k	Nessun dato

2.9yrs

Durata media

Gestione esperta: Il team dirigenziale di ONCY è considerato esperto (durata media dell'incarico 2.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Wayne Pisano	Interim CEO & Chairman of the Board	11.5yrs	CA$165.01k	0.25% $ 190.4k
Bernd Seizinger	Independent Director	9.4yrs	CA$123.96k	0.49% $ 381.0k
James Parsons	Independent Director	2.4yrs	CA$116.36k	Nessun dato
Jonathan M. Rigby	Independent Director	2.3yrs	CA$107.40k	0.41% $ 315.6k
Patricia S. Andrews	Independent Director	less than a year	Nessun dato	Nessun dato
Angela Holtham	Independent Director	10.4yrs	CA$130.58k	0.17% $ 127.5k
Jean-Pierre Bizzari	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Padmanee Sharma	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Dirk Arnold	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Deborah Brown	Independent Director	7yrs	CA$124.95k	0.064% $ 49.1k
Martine Piccart	Member of Scientific Advisory Board	7yrs	Nessun dato	Nessun dato
Richard Vile	Member of Scientific Advisory Board	4.1yrs	Nessun dato	Nessun dato

5.5yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ONCY sono considerati esperti (durata media dell'incarico 5.5 anni).

Oncolytics Biotech Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Oncolytics Biotech Inc., Annual General Meeting, May 15, 2024

Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors

Oncolytics Biotech(R) Appoints Jonathan Rigby to Its Board of Directors

Independent Director recently bought US$43k worth of stock

Oncolytics Biotech Inc. Appoints James T. Parsons to its Board of Directors

Oncolytics Biotech Inc., Annual General Meeting, Jun 16, 2022

Recent updates

New major risk - Financial position

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech Inc., Annual General Meeting, May 15, 2024

New minor risk - Profitability

Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors

Forecast to breakeven in 2026

Oncolytics Biotech Inc. Announces the Anal Cancer Cohort of the Goblet Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

New minor risk - Share price stability

Oncolytics Biotech Inc. Presents Further Positive Pelareorep Translational Data At SITC

Oncolytics Biotech Inc. Announces Poster Presentation of Positive, Updated Results from the Phase 1/2 GOBLET Study

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the Goblet Study

Oncolytics Biotech Inc. Unveils Results from Its Phase 2 Trial of A Drug for Metastatic Breast Cancer

Oncolytics Biotech Inc. has completed a Composite Units Offering in the amount of $15.00075 million.

New major risk - Share price stability

Oncolytics Biotech Inc. Announces Selection of Pelareorep for Inclusion as New Investigational Treatment in Precision Promise, an Innovative Adaptive Phase 3 Clinical Trial

New minor risk - Market cap size

Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Oncolytics Biotech Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives 50% Improvements in ORR and mPFS

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting

Oncolytics Biotech(R) Appoints Jonathan Rigby to Its Board of Directors

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

Independent Director recently bought US$43k worth of stock

Oncolytics Biotech Inc. Appoints James T. Parsons to its Board of Directors

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

Oncolytics Biotech Inc. Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with Chimeric Antigen Receptor T Cell Therapy in Solid Tumors

Oncolytics Biotech Inc. Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting

Oncolytics Biotech Inc., Annual General Meeting, Jun 16, 2022

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of Its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech Inc. Promotes Thomas C. Heineman to Chief Medical Officer

No longer forecast to breakeven

Oncolytics Biotech® Inc. Provides Positive Safety Update on Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech® Inc. Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Oncolytics Biotech Inc. Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

No longer forecast to breakeven

Oncolytics Biotech Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy

No longer forecast to breakeven

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-Of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

Oncolytics Biotech reports Q1 results

Oncolytics Biotech Inc., Annual General Meeting, May 07, 2021

Oncolytics Biotech Inc. Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors

New 90-day high: US$2.63

Oncolytics Biotech Announces Positive Clinical Results against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting

Oncolytics Biotech® Inc. and Solti-Innovative Breast Cancer Research Announce the Publication of an Electronic Poster with Clinical Data from the Aware-1 Window-Of-Opportunity Breast Cancer Study At the Society for Immunotherapy of Cancer

Oncolytics Biotech Inc. Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor

New 90-day high: US$2.27

Oncolytics Biotech Inc. Appoints Richard Vile, Ph.D., to Its Scientific Advisory Board

New 90-day low - US$1.59

New 90-day low - US$1.67

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media